These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 20133820)

  • 21. Subependymal giant-cell astrocytomas in the absence of tuberous sclerosis.
    Reynolds RA; Aum DJ; Gonzalez-Gomez I; Wong M; Roberts K; Dahiya S; Rodriguez LF; Roland JL; Smyth MD
    J Neurosurg Pediatr; 2023 Sep; 32(3):351-357. PubMed ID: 37327147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subependymal Giant Cell Astrocytomas in Tuberous Sclerosis Complex-Current Views on Their Pathogenesis and Management.
    Gao C; Zabielska B; Jiao F; Mei D; Wang X; Kotulska K; Jozwiak S
    J Clin Med; 2023 Jan; 12(3):. PubMed ID: 36769603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tuberous sclerosis complex neuropathology requires glutamate-cysteine ligase.
    Malik AR; Liszewska E; Skalecka A; Urbanska M; Iyer AM; Swiech LJ; Perycz M; Parobczak K; Pietruszka P; Zarebska MM; Macias M; Kotulska K; Borkowska J; Grajkowska W; Tyburczy ME; Jozwiak S; Kwiatkowski DJ; Aronica E; Jaworski J
    Acta Neuropathol Commun; 2015 Jul; 3():48. PubMed ID: 26220190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
    Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA
    Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.
    Tomoto K; Fujimoto A; Inenaga C; Okanishi T; Imai S; Ogai M; Fukunaga A; Nakamura H; Sato K; Obana A; Masui T; Arai Y; Enoki H
    BMC Neurol; 2021 Mar; 21(1):139. PubMed ID: 33784976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mammalian Target of Rapamycin Inhibitor Induced Complete Remission of a Recurrent Subependymal Giant Cell Astrocytoma in a Patient Without Features of Tuberous Sclerosis Complex.
    Appalla D; Depalma A; Calderwood S
    Pediatr Blood Cancer; 2016 Jul; 63(7):1276-8. PubMed ID: 26929034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Congenital subependymal giant cell astrocytomas in patients with tuberous sclerosis complex.
    Kotulska K; Borkowska J; Mandera M; Roszkowski M; Jurkiewicz E; Grajkowska W; Bilska M; Jóźwiak S
    Childs Nerv Syst; 2014 Dec; 30(12):2037-42. PubMed ID: 25227171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
    Curatolo P
    Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolated subependymal giant cell astrocytoma (SEGA) in the absence of clinical tuberous sclerosis: two case reports and literature review.
    Cobourn KD; Chesney KM; Mueller K; Fayed I; Tsering D; Keating RF
    Childs Nerv Syst; 2024 Jan; 40(1):73-78. PubMed ID: 37658938
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
    Mateos-González ME; López-Laso E; Vicente-Rueda J; Camino-León R; Fernández-Ramos JA; Baena-Gómez MA; Peña-Rosa MJ
    Rev Neurol; 2014 Dec; 59(11):497-502. PubMed ID: 25418144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
    Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
    J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
    Trelinska J; Dachowska I; Kotulska K; Baranska D; Fendler W; Jozwiak S; Mlynarski W
    Pediatr Blood Cancer; 2015 Apr; 62(4):616-21. PubMed ID: 25557360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
    Franz DN
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex.
    Liang N; Zhang C; Dill P; Panasyuk G; Pion D; Koka V; Gallazzini M; Olson EN; Lam H; Henske EP; Dong Z; Apte U; Pallet N; Johnson RL; Terzi F; Kwiatkowski DJ; Scoazec JY; Martignoni G; Pende M
    J Exp Med; 2014 Oct; 211(11):2249-63. PubMed ID: 25288394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex.
    Parker WE; Orlova KA; Heuer GG; Baybis M; Aronica E; Frost M; Wong M; Crino PB
    Am J Pathol; 2011 Jan; 178(1):296-305. PubMed ID: 21224066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TSC2 somatic mosaic mutation, including extra-tumor tissue, may be the developmental cause of solitary subependymal giant cell astrocytoma.
    Sasaki T; Uda T; Kuki I; Kunihiro N; Okazaki S; Niida Y; Goto T
    Childs Nerv Syst; 2022 Jan; 38(1):77-83. PubMed ID: 34741623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Stress-Induced Atf3-Gelsolin Cascade Underlies Dendritic Spine Deficits in Neuronal Models of Tuberous Sclerosis Complex.
    Nie D; Chen Z; Ebrahimi-Fakhari D; Di Nardo A; Julich K; Robson VK; Cheng YC; Woolf CJ; Heiman M; Sahin M
    J Neurosci; 2015 Jul; 35(30):10762-72. PubMed ID: 26224859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC.
    Jancic J; Duric V; Ivancevic N; Nikolic B; van den Anker JN; Samardzic J
    Curr Med Chem; 2016; 23(37):4260-4269. PubMed ID: 27739368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.